The Next Wave of ADCs Could Treat Evasive Solid Tumor 👨🔬 Advances in antibody-drug conjugates, including novel payloads and new targets, will be featured at the American Association for Cancer Research's annual conference, taking place this week in San Diego, where companies, including Elevation Oncology and Tubulis, will present new data from their respective programs. 👩🔬 Take a look at the full article here - BioSpace - https://lnkd.in/ewwP3NUn #biotech #biotechnology #biology #technology
Trending Now Biotech’s Post
More Relevant Posts
-
What happens when chemical engineering meets biomedicine? ✨ World, meet R3CE A game-changing 3D culture platform provides researchers with the means to delve deep into the realms of cancer research, clinical treatments, and drug discovery. R3CE stands for "Rapid, Reproducible, and Rare Cell 3D Expansion." The revolutionary technique allows rare cells, such as CTC, to be captured and cultivated for subsequent research. Our groundbreaking research has now set its sights on breast, lung, and colon cancer, promising new horizons in understanding and combating these diseases. Follow us on LinkedIn for the latest insights and discoveries! #AcroCyte #3DCellCulture #PrecisionMedicine #CirculatingTumorCell #Organoid #Cancer #DrugDiscovery
-
🌟 Going to Cell Symposia in San Diego next week? Swing by our poster to learn more about how we are using #AI to enhance #drug response profiling! 🗓 Schedule a meeting to talk one-on-one with Evan Cromwell to learn how the Pu·MA System can streamline your 3D cell based assay workflow https://lnkd.in/g5ikCFZ4
📢 Come see our #poster Drug response profiling of individual primary colorectal cancer #tumoroids using a novel automation workflow and #AI-assisted image analysis at Cell Symposia in San Diego later this month! Presenter: Anthony Eritano, PhD (Senior Scientist, Scienion), in collaboration with SCIENION & MatTek Life Sciences Poster & Event Details: https://lnkd.in/gSsp-KsY
-
-
Excited to share for the first time the structure and the biochemical mechanism of action of our STAT3 degrader KT-333. In Kirti Sharma’s presentation you’ll learn how we select the right E3 ligase for each target and the in depth characterization of ternary complex structures including cryo EM. Using VHL for this target was driven by biological as well as biochemical preferences of this E3 vs CRBN or other E3 ligases. Please stop by this poster or download it from our website and if you can join my presentation tomorrow on “Targeting Validated but Un-Drugged Oncogenes with Small Molecule Protein Degraders”.
Check out our presentations at the American Association for Cancer Research Annual Meeting! Our late-breaking poster highlights preclinical data on the novel E3 pairing and structural mechanisms underlying antitumor activity of KT-333, our first-in-class STAT3 degrader, and our CEO, Nello Mainolfi, will be a featured speaker in a Major Symposium to discuss our unique drug discovery and translational strategies. Learn more: https://bit.ly/49sfXph #AACR24 #TPD #ReinventingMedicine
-
-
What a fantastic article by Natalya Ortolano interviewing bioengineer Matthew Ishahak, a postdoctoral research scholar in the lab for Dr. Jeffrey Millman at the Washington University School of Medicine in St. Louis! Matt used 10x Genomics "single cell sequencing (#Chromium #SingleCell Gene Expression) and single cell #spatial transcriptomics (#Xenium #InSitu) to see that engineered #glioblastoma brain organoids (eGBOs) displayed expected differences in cell state and spatial architecture based on the initial mutation. As far as the greater impact of the research, in Matt's words, "As we start to have a deeper understanding of the altered gene expression and spatial organization of these diseases using engineered models like eGBOs, that will provide another readout for drug screening. Having those additional readouts can only improve drug discovery" Xenium work was done through The McDonnell Genome Institute, WashU Medicine. References: Ishahak M, et al. Modeling glioblastoma tumor progression via CRISPR-engineered brain organoids. bioRxiv (2024).
Read our interview with bioengineer Matthew Ishahak, PhD, from WashU about his new organoid model for studying glioblastoma tumorigenesis, and his perspective on how #spatialtranscriptomics will transform cancer drug discovery: https://bit.ly/3zrJnYV
-
-
The Scientific Director of Genekor Medical S.A. and Molecular Biologist, PhD, George Nasioulas gave a speech on: "Liquid Biopsy and NGS: the logarithmic increase of information in 2024" at the 3rd Panhellenic Congress of Cancer Therapeutics held on 28-30/3/2024. Dr. Nasioulas emphasized that the information we now get using liquid biopsy (blood) gives all the information we used to get from tissue in surgical biopsies. A prerequisite for this is the use of next-generation NGS analyzers. #Genekor #NGS #LiquidBiopsy
-
-
Discover Approaches to Develop & Analyze physiologically relevant Tumor Spheroids https://lnkd.in/geuAk6UZ Attending #CellBio2023? Stop by our poster #P2711 titled 'Multicellular tumor spheroids for mimicking the tumor microenvironment in-vitro' on December 5th, 12:15-1:45 PM EST, board #B255. Discover approaches you can take to create physiologically relevant tumor models for drug screening applications and for understanding cancer biology. #Thermofisherscientific #research #antibodies #cellbio2023 #microscopy #stemcells #ASCB2023 #imaging #organoid #TumorSpheroid
-
-
Hot off the press! Read the August issue of Bio-Rad’a BioRadiations for my article introducing the new ChemiDoc Go Imaging System! It’s never been easier to acquire, save, analyze, report, and publish your gel and western blot images. #westernblot #gelimaging #lifescience
Explore BioRad’s August issue: https://lnkd.in/gEr-tns6 Unveil the new ChemiDoc Go Imaging System, explore ctDNA analysis for breast cancer, and get insights from SLAS highlights. Learn about advanced purification, real-time PCR tips, and more. Tune in to BioRad.io Episode #21 for a glimpse into the future lab! Don’t miss site updates, product announcements, new lab techniques, and breaking scientific stories. Subscribe to get the latest in your email! ➡️https://lnkd.in/gze-Xesb #Bioradiations #LifeScience #Biotechnology
-
Read our interview with bioengineer Matthew Ishahak, PhD, from WashU about his new organoid model for studying glioblastoma tumorigenesis, and his perspective on how #spatialtranscriptomics will transform cancer drug discovery: https://bit.ly/3zrJnYV
-
-
Capture customized insights for #tumor genomic profiling with new Agilent Technologies SureSelect Cancer Custom panels, designed using the simple, intuitive Agilent SureDesign web portal. Tune into this webinar to learn how to design #NGS cancer assays tailored to your research goals, including the addition of new and emerging #biomarkers. https://bit.ly/4apq52y
-
-
I am pleased to announce the completion of my thesis titled "Nanocarriers for Targeted Drug Delivery in Cancer Treatment". This work explores innovative approaches to improve the precision of chemotherapy by utilizing nanotechnology to target tumor cells directly, reducing side effects and improving patient outcomes. Key findings demonstrate that specific nanocarrier designs can significantly optimize the delivery of therapeutic agents, providing new avenues for cancer treatment strategies. The collaboration with my advisors and peers has been instrumental in the success of this project. #CancerResearch #Nanotechnology #DrugDelivery #ThesisCompletion #Pharmacology
-
Thank you for sharing!